China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia, a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).
Combining Expertise
The partnership combines Biocytogen’s RenLite platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology. This strategic combination is expected to address some of the most challenging issues in oncology, specifically tumor heterogeneity and drug resistance, by employing a dual-payload approach.
Significance of the Partnership
This collaboration underscores the commitment of both Biocytogen and Acepodia to advancing innovative therapies in oncology. By leveraging their respective technologies, the companies aim to develop more effective treatments that can overcome the complexities of tumor heterogeneity and drug resistance, ultimately improving patient outcomes.
